E-viri
PDF
Recenzirano
Odprti dostop
-
O'Dell, Sijy; Talana, Chloe A; Lai, Lilin; Corbett, Kizzmekia S; Jackson, Lisa; Leav, Brett; Luke, Catherine J; Makowski, Mat; Roberts, Paul C; Rebolledo, Paulina A; Rouphael, Nadine G; Wang, Lingshu; Widge, Alicia T; Graham, Barney S; Mascola, John R; Doria-Rose, Nicole A; Arega, Jae; Buchanan, Wendy; Elsafy, Mohammed; Lampley, Rebecca; Kolhekar, Aparna; Luke, Catherine; Makhene, Mamodikoe; Pikaart-Tautges, Rhonda; Roberts, Paul C; Russell, Janie; Albert, Jim; Kunwar, Pratap; Makowski, Mat; Anderson, Evan J; Bechnak, Amer; Camacho-Gonzalez, Andres F; Drobeniuc, Ana; Edara, Venkata Viswanadh; Edupuganti, Srilatha; Floyd, Katharine; Gibson, Theda; Ackerley, Cassie M Grimsley; Johnson, Brandi; Kao, Carol; Lai, Lilin; Macenczak, Hollie; McCullough, Michele Paine; Peters, Etza; Phadke, Varun K; Rebolledo, Paulina A; Rouphael, Nadine; Scherer, Erin; Sherman, Amy; Stephens, Kathy; Winston, Juton; Barr, Lee; Benoit, Joyce; Carste, Barbara; Choe, Joe; Ffitch, Jana; Fields, Colin; Jackson, Lisa A; Lasicka, Susan; Pimienta, Stephanie; Suyehira, Janice; Witte, Michael; Bennett, Hamilton; Altaras, Nedim Emil; Carfi, Andrea; Leav, Brett; Zaks, Tal; Coler, Rhea N; Larsen, Sasha E; Lindesmith, Lisa C; Martinez, David R; Edwards, Caitlin; Baric, Ralph S; Berkowitz, Nina M; Boritz, Eli A; Carlton, Kevin; Corbett, Kizzmekia S; Costner, Pamela; Creanga, Adrian; Douek, Daniel C; Flach, Britta; Gordon, Ingelise; Graham, Barney S; Holman, LaSonji; Lin, Bob C; Morabito, Kaitlyn M; Novik, Laura; O'Connell, Sarah; O'Dell, Sijy; Swanson, 2nd, Phillip A; Talana, Chloe A; Wang, Lingshu; Widge, Alicia T; Yang, Eun Sung; Hughes, Tia; Pruijssers, Andrea J; Stevens, Laura J; Posavad, Christine M; Gale, Jr, Michael; Menachery, Vineet
Science (American Association for the Advancement of Science), 09/2021, Letnik: 373, Številka: 6561Journal Article
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)–competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
